<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539616</url>
  </required_header>
  <id_info>
    <org_study_id>ZYH7.10.001.01</org_study_id>
    <secondary_id>CTRI/2011/11/002147</secondary_id>
    <nct_id>NCT01539616</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia</brief_title>
  <official_title>A Multicentric Prospective Randomized Double Blind Parallel Group Active Controlled Study to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadila Healthcare Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cadila Healthcare Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ZYH7, a novel peroxisome proliferator-activated receptor (PPAR) alpha agonist, is expected to
      decrease triglyceride level and also correct dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in mean triglyceride level from baseline</measure>
    <time_frame>4 and 8 weeks</time_frame>
    <description>Percentage change in mean triglyceride levels from baseline within and across each treatment of ZYH7 The changes will be compared with fenofibrate 160mg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in lipid parameters</measure>
    <time_frame>4 and 8 weeks</time_frame>
    <description>Percentage change from baseline in the following lipid parameters:
Low Density Lipoprotein Cholesterol(LDL)
Very Low Density Lipoprotein Cholesterol (VLDL)
High Density Lipoprotein (HDL)
Total cholesterol
Non HDL Cholesterol (Measured value)
Apo A
Apo B
High sensitive C-Reactive Protein (hs-CRP)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>ZYH7 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZYH7 4mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZYH7 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZYH7 8mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZYH7 16mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZYH7 16mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenofibrate 160mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fenofibrate 160mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZYH7</intervention_name>
    <description>ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.</description>
    <arm_group_label>ZYH7 4mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZYH7</intervention_name>
    <description>ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.</description>
    <arm_group_label>ZYH7 8mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZYH7</intervention_name>
    <description>ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.</description>
    <arm_group_label>ZYH7 16mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.</description>
    <arm_group_label>Fenofibrate 160mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-65 years

          2. Subjects of either gender, males or females

          3. Triglycerides between 200 to 500 mg/dl on screening visit.

          4. Body mass index (BMI) &gt; 23 kg/m2

          5. If subject is diabetic, he should be controlled on a maximum of two oral anti diabetic
             agents except Thiazolidinedione.

          6. Subject has given informed consent for participation in this trial.

        Exclusion Criteria:

          1. Pregnancy and lactation.

          2. History of 5% weight loss in past 6 months.

          3. Subjects on treatment with insulin and PPAR alpha or gamma agonist in the past 3
             month.

          4. Subjects having unstable angina, acute myocardial infarction in past 3 months or heart
             failure of New York Heart Association (NYHA) class (III-IV).

          5. Uncontrolled hypertension (150/100 mm of Hg).(If Subject using Thiazides, ACE
             inhibitors, beta blockers they should be on minimum 3 month stable therapy and
             treatment not expected to change during trial participation)

          6. History of clinically significant edema.

          7. History of pancreatitis or gall stone diseases.

          8. Subject having thyroid-stimulating hormone (TSH) levels outside normal reference
             range, Subjects who are clinically euthyroid and on stable thyroid replacement therapy
             for 2 months prior to screening and who are anticipated to remain on this dose
             throughout the trial period will be allowed.

          9. Uncontrolled diabetes (HbA1c ≥ 9 gm %).

         10. History of active liver disease or hepatic dysfunction demonstrated by aspartate
             aminotransferase (AST) and Alanine Aminotransferase(ALT) ≥ 2.5 times of upper normal
             limit (UNL) or bilirubin ≥ 2 times UNL in the past 3 months.

         11. Renal dysfunction demonstrated by abnormal Glomerular Filtration Rate (GFR) (60
             ml/min) or presence of ketonuria.

         12. History of myopathies or evidence of active muscle diseases demonstrated by Creatinine
             Phosphokinase(CPK) ≥ 10 times UNL.

         13. History of any other concurrent serious illness (e.g. tuberculosis, Human
             Immunodeficiency Virus(HIV) infection, malignancy, etc).

         14. History of alcohol and/or drug abuse.

         15. History of known allergy, sensitivity or intolerance to the study drugs and their
             formulation ingredients.

         16. Subjects on any other lipid lowering medications. (Appendix I).

         17. If on contraceptive or hormone replacement therapy (HRT), therapy started or changed
             in last 3 months.

         18. Prolonged use of steroids (15 days) in last 3 months (topical preparations, nasal and
             intra-articular administration are permitted).

         19. History of long term use of non-steroidal anti-inflammatory drugs. (1 month)

         20. Participation in any other clinical trial in the past 3 months

         21. Unable to give informed consent and follow protocol requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajendra H Jani, Ph.D (Medical)</last_name>
    <role>Study Director</role>
    <affiliation>Head &amp; Senior Vice President, Clinical R&amp;D, Cadila Healthcare Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vijayratna Diabetes Diagnosis &amp; Treatment Centre, Upper Ground Floor, Sumeru Centre, Nr Parimal Underbridge, Paldi</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Devi Hospital,Ground floor, Naranpura</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private clinic, 4, Stadium House, Ground Floor, Navrangpura</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dia Care Reseach, 1&amp;2- Gandhi Park Society, Nr. Nehrunagar Cross Roads, Ambawadi</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Govt. Medical College, Bhavnagar</name>
      <address>
        <city>Bhavnagar</city>
        <state>Gujarat</state>
        <zip>364001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrocare Clinic,Ground floor, Karansinhji Main Road,</name>
      <address>
        <city>Rajkot</city>
        <state>Gujarat</state>
        <zip>360001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Balaji Hospital,First floor,clinical research department, Opp. Vidya Vikas School, Subhanpura,</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390 023</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pace Clinical Research (A. Unit of Pranav Diabetes Centre), No. 53, Nanda Complex, Ramamurthy Nagar Main Road, Banasawadi</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 043</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinivasa clinic and Diabetic Care centre, 197, 2nd floor, Near Avalahalli BDA park, BSK 3rd stage</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560085</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mallige Healthcare Centre, # 402, 8th main, 8th cross, Near Dr. M. C. Modi Compound. P.J.EXTN,</name>
      <address>
        <city>Davangere</city>
        <state>Karnataka</state>
        <zip>577002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deogiri Diabetes Centre, 46 Samata Nagar, Near Kranti Chowk Police Station</name>
      <address>
        <city>Aurangabad</city>
        <state>Maharashtra</state>
        <zip>431001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhatia Hospital, Tardeo Road,Room no 19, Basement floor,Research room,</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pai Clinic &amp; Diagnostic Centre - Abhinav Apartments, 778/B-4, First floor, Shivajinagar, Next to Congress House</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shree Nidan Hospital, Clinical trial department, First floor, 27-28 Vidhyut nagar-A, Ajmer road</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302024</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mother's Care Diabetes Centre, Room no 9, Phase 1, Sathuvachari</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aruna Diabetes Centre, 56,Thiruvengatapuram, Near Nungambakkam Railway Station, Choolamedu</name>
      <address>
        <city>Chennai</city>
        <state>Tamilnadu</state>
        <zip>600094</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology, Room No.9, 4 th Floor, Ronald Ross Building, Institute of Post Graduate Medical Education &amp; Research, 244 AJC Bose Road.</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Room no 3027,Research block B,Department of Endocrinology PGIMER</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2012</study_first_posted>
  <last_update_submitted>October 25, 2013</last_update_submitted>
  <last_update_submitted_qc>October 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertriglyceridemia</keyword>
  <keyword>Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

